🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Singapore / NCT07444073
Starting soon Observational

Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

NCT07444073 · tracked via the Priya Life Science Singapore tracker
Phase
Observational
Started
2026-06-01
Last updated
2026-07-01

Condition(s) studied

AgingObesity & Overweight

Investigational drug(s) / intervention(s)

Not applicable. This is an observational study.

Not applicable. This is an observational study.: Not applicable. This is an observational study.

Study summary

This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.

Eligibility

Sex
ALL
Min age
40 Years
Max age
89 Years
Healthy volunteers
No
Inclusion Criteria * Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program. * BMI of ≥ 30 kg/m2 (obesity); OR * BMI of ≥ 27 kg/m2 to \< 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Exclusion Criteria * Pregnancy or lactation. * Non-ambulatory status, total blindness, complete hearing loss, or inability to speak. * Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes. * On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months. * Active cancer on chemotherapy or immunotherapy. * Known hypersensitivity or contraindications to GLP-1 RAs. * Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
NOVI Health (T3 Health PTE LTD) Singapore Singapore
National University of Singapore Singapore Singapore

More National University of Singapore trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07444073 on ClinicalTrials.gov ↗ ← All trials in Singapore